KR20020031111A - 홍삼 및 인삼 엑기스 분말을 함유한 마이크로캡슐 - Google Patents
홍삼 및 인삼 엑기스 분말을 함유한 마이크로캡슐 Download PDFInfo
- Publication number
- KR20020031111A KR20020031111A KR1020020003276A KR20020003276A KR20020031111A KR 20020031111 A KR20020031111 A KR 20020031111A KR 1020020003276 A KR1020020003276 A KR 1020020003276A KR 20020003276 A KR20020003276 A KR 20020003276A KR 20020031111 A KR20020031111 A KR 20020031111A
- Authority
- KR
- South Korea
- Prior art keywords
- ginseng
- red ginseng
- cellulose
- extract powder
- people
- Prior art date
Links
- 235000002789 Panax ginseng Nutrition 0.000 title claims abstract description 70
- 239000000843 powder Substances 0.000 title claims abstract description 38
- 239000003094 microcapsule Substances 0.000 title claims abstract description 19
- 235000020710 ginseng extract Nutrition 0.000 title claims abstract description 18
- 235000019658 bitter taste Nutrition 0.000 title abstract description 17
- 230000000873 masking effect Effects 0.000 title description 3
- 239000000463 material Substances 0.000 claims abstract description 31
- 239000011248 coating agent Substances 0.000 claims abstract description 27
- 238000000576 coating method Methods 0.000 claims abstract description 27
- 229920003145 methacrylic acid copolymer Polymers 0.000 claims abstract description 26
- 229920000642 polymer Polymers 0.000 claims abstract description 23
- -1 fatty acid ester Chemical class 0.000 claims abstract description 14
- 229920002678 cellulose Polymers 0.000 claims abstract description 12
- 239000001913 cellulose Substances 0.000 claims abstract description 12
- 235000014113 dietary fatty acids Nutrition 0.000 claims abstract description 12
- 239000000194 fatty acid Substances 0.000 claims abstract description 12
- 229930195729 fatty acid Natural products 0.000 claims abstract description 12
- 239000002861 polymer material Substances 0.000 claims abstract description 6
- 239000002245 particle Substances 0.000 claims abstract description 5
- 235000013361 beverage Nutrition 0.000 claims abstract description 4
- 235000009508 confectionery Nutrition 0.000 claims abstract description 4
- 239000002537 cosmetic Substances 0.000 claims abstract description 4
- 229940117841 methacrylic acid copolymer Drugs 0.000 claims description 23
- 235000021355 Stearic acid Nutrition 0.000 claims description 19
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 19
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 19
- 239000008117 stearic acid Substances 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 18
- 239000001856 Ethyl cellulose Substances 0.000 claims description 13
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 13
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 13
- 229920001249 ethyl cellulose Polymers 0.000 claims description 13
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims description 12
- 229920003138 Eudragit® L 30 D-55 Polymers 0.000 claims description 6
- GWFGDXZQZYMSMJ-UHFFFAOYSA-N Octadecansaeure-heptadecylester Natural products CCCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCCCC GWFGDXZQZYMSMJ-UHFFFAOYSA-N 0.000 claims description 6
- GDCRSXZBSIRSFR-UHFFFAOYSA-N ethyl prop-2-enoate;2-methylprop-2-enoic acid Chemical compound CC(=C)C(O)=O.CCOC(=O)C=C GDCRSXZBSIRSFR-UHFFFAOYSA-N 0.000 claims description 6
- NKBWPOSQERPBFI-UHFFFAOYSA-N octadecyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCCCC NKBWPOSQERPBFI-UHFFFAOYSA-N 0.000 claims description 6
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 claims description 5
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims description 4
- 229920001577 copolymer Polymers 0.000 claims description 4
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 claims description 4
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims description 4
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 4
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 4
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 4
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 4
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 claims description 4
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 claims description 2
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 claims description 2
- 229920000623 Cellulose acetate phthalate Polymers 0.000 claims description 2
- 235000021314 Palmitic acid Nutrition 0.000 claims description 2
- IYFATESGLOUGBX-YVNJGZBMSA-N Sorbitan monopalmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O IYFATESGLOUGBX-YVNJGZBMSA-N 0.000 claims description 2
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 claims description 2
- IYKJEILNJZQJPU-UHFFFAOYSA-N acetic acid;butanedioic acid Chemical compound CC(O)=O.OC(=O)CCC(O)=O IYKJEILNJZQJPU-UHFFFAOYSA-N 0.000 claims description 2
- 229920002301 cellulose acetate Polymers 0.000 claims description 2
- 229920006217 cellulose acetate butyrate Polymers 0.000 claims description 2
- 229940081734 cellulose acetate phthalate Drugs 0.000 claims description 2
- 229940082500 cetostearyl alcohol Drugs 0.000 claims description 2
- 229960000541 cetyl alcohol Drugs 0.000 claims description 2
- 229940049654 glyceryl behenate Drugs 0.000 claims description 2
- 229940075507 glyceryl monostearate Drugs 0.000 claims description 2
- FETSQPAGYOVAQU-UHFFFAOYSA-N glyceryl palmitostearate Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O FETSQPAGYOVAQU-UHFFFAOYSA-N 0.000 claims description 2
- 229940046813 glyceryl palmitostearate Drugs 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 claims description 2
- 229920000609 methyl cellulose Polymers 0.000 claims description 2
- 239000001923 methylcellulose Substances 0.000 claims description 2
- 235000010981 methylcellulose Nutrition 0.000 claims description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 claims description 2
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 claims description 2
- DOKHEARVIDLSFF-UHFFFAOYSA-N prop-1-en-1-ol Chemical class CC=CO DOKHEARVIDLSFF-UHFFFAOYSA-N 0.000 claims description 2
- 239000001570 sorbitan monopalmitate Substances 0.000 claims description 2
- 235000011071 sorbitan monopalmitate Nutrition 0.000 claims description 2
- 229940031953 sorbitan monopalmitate Drugs 0.000 claims description 2
- 239000001587 sorbitan monostearate Substances 0.000 claims description 2
- 235000011076 sorbitan monostearate Nutrition 0.000 claims description 2
- 229940035048 sorbitan monostearate Drugs 0.000 claims description 2
- 229940012831 stearyl alcohol Drugs 0.000 claims description 2
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 claims description 2
- 235000013402 health food Nutrition 0.000 abstract description 8
- 239000000203 mixture Substances 0.000 abstract description 6
- 239000012530 fluid Substances 0.000 abstract 2
- 239000011162 core material Substances 0.000 abstract 1
- 235000008434 ginseng Nutrition 0.000 description 44
- 241000208340 Araliaceae Species 0.000 description 43
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 43
- 235000003140 Panax quinquefolius Nutrition 0.000 description 43
- 230000000694 effects Effects 0.000 description 29
- 239000000284 extract Substances 0.000 description 28
- 230000000052 comparative effect Effects 0.000 description 11
- 239000000047 product Substances 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 8
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 8
- 229930182490 saponin Natural products 0.000 description 8
- 150000007949 saponins Chemical class 0.000 description 8
- 206010028980 Neoplasm Diseases 0.000 description 7
- 201000011510 cancer Diseases 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 239000002246 antineoplastic agent Substances 0.000 description 4
- 230000000903 blocking effect Effects 0.000 description 4
- 238000004090 dissolution Methods 0.000 description 4
- 238000007922 dissolution test Methods 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 238000005507 spraying Methods 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 3
- 229940041181 antineoplastic drug Drugs 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 235000019441 ethanol Nutrition 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- RXZBMPWDPOLZGW-XMRMVWPWSA-N (E)-roxithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=N/OCOCCOC)/[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 RXZBMPWDPOLZGW-XMRMVWPWSA-N 0.000 description 2
- 229920003134 Eudragit® polymer Polymers 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 208000007107 Stomach Ulcer Diseases 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 238000001467 acupuncture Methods 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- HIMXGTXNXJYFGB-UHFFFAOYSA-N alloxan Chemical compound O=C1NC(=O)C(=O)C(=O)N1 HIMXGTXNXJYFGB-UHFFFAOYSA-N 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000001784 detoxification Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 239000003120 macrolide antibiotic agent Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 229960005224 roxithromycin Drugs 0.000 description 2
- 230000001953 sensory effect Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- CKUVNOCSBYYHIS-UHFFFAOYSA-N (20R)-ginsenoside Rg3 Natural products CC(C)=CCCC(C)(O)C1CCC(C2(CCC3C4(C)C)C)(C)C1C(O)CC2C3(C)CCC4OC1OC(CO)C(O)C(O)C1O CKUVNOCSBYYHIS-UHFFFAOYSA-N 0.000 description 1
- HMUNWXXNJPVALC-UHFFFAOYSA-N 1-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C(CN1CC2=C(CC1)NN=N2)=O HMUNWXXNJPVALC-UHFFFAOYSA-N 0.000 description 1
- HGUFODBRKLSHSI-UHFFFAOYSA-N 2,3,7,8-tetrachloro-dibenzo-p-dioxin Chemical compound O1C2=CC(Cl)=C(Cl)C=C2OC2=C1C=C(Cl)C(Cl)=C2 HGUFODBRKLSHSI-UHFFFAOYSA-N 0.000 description 1
- YLZOPXRUQYQQID-UHFFFAOYSA-N 3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]propan-1-one Chemical compound N1N=NC=2CN(CCC=21)CCC(=O)N1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F YLZOPXRUQYQQID-UHFFFAOYSA-N 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 108010087765 Antipain Proteins 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 101100297345 Caenorhabditis elegans pgl-2 gene Proteins 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- FPVVYTCTZKCSOJ-UHFFFAOYSA-N Ethylene glycol distearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCOC(=O)CCCCCCCCCCCCCCCCC FPVVYTCTZKCSOJ-UHFFFAOYSA-N 0.000 description 1
- 206010019133 Hangover Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 235000019596 Masking bitterness Nutrition 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 206010027304 Menopausal symptoms Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 240000004371 Panax ginseng Species 0.000 description 1
- 206010062237 Renal impairment Diseases 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 206010042220 Stress ulcer Diseases 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000049 anti-anxiety effect Effects 0.000 description 1
- 230000003217 anti-cancerogenic effect Effects 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 230000000561 anti-psychotic effect Effects 0.000 description 1
- 230000002180 anti-stress Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 229940125708 antidiabetic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- SDNYTAYICBFYFH-TUFLPTIASA-N antipain Chemical compound NC(N)=NCCC[C@@H](C=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 SDNYTAYICBFYFH-TUFLPTIASA-N 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000004531 blood pressure lowering effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 230000009702 cancer cell proliferation Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 230000009084 cardiovascular function Effects 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000010307 cell transformation Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 230000006353 environmental stress Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 150000004678 hydrides Chemical class 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 239000005555 hypertensive agent Substances 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 230000007688 immunotoxicity Effects 0.000 description 1
- 231100000386 immunotoxicity Toxicity 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 230000002608 insulinlike Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000006984 memory degeneration Effects 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000003961 neuronal insult Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 230000003836 peripheral circulation Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000009862 primary prevention Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 230000007420 reactivation Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 230000007958 sleep Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- DSNBHJFQCNUKMA-SCKDECHMSA-N thromboxane A2 Chemical compound OC(=O)CCC\C=C/C[C@@H]1[C@@H](/C=C/[C@@H](O)CCCCC)O[C@@H]2O[C@H]1C2 DSNBHJFQCNUKMA-SCKDECHMSA-N 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
- 230000000304 vasodilatating effect Effects 0.000 description 1
- 230000001196 vasorelaxation Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/30—Encapsulation of particles, e.g. foodstuff additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
- A23V2250/2124—Ginseng
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
구분 | 쓴맛을 느낌 | 쓴맛이 약간느낌 | 쓴맛이 없음 | 모르겠음 |
실시예 1 | 0 명 | 0 명 | 20 명 | 0 명 |
실시예 2 | 0 명 | 0 명 | 20 명 | 0 명 |
실시예 3 | 0 명 | 2 명 | 17 명 | 1 명 |
실시예 4 | 0 명 | 5 명 | 14 명 | 1 명 |
실시예 5 | 0 명 | 4 명 | 15 명 | 1 명 |
실시예 6 | 0 명 | 0 명 | 20 명 | 0 명 |
실시예 7 | 0 명 | 3 명 | 15 명 | 2 명 |
실시예 8 | 0 명 | 1 명 | 18 명 | 1 명 |
실시예 9 | 0 명 | 1 명 | 18 명 | 1 명 |
실시예 10 | 0 명 | 0 명 | 19 명 | 1 명 |
실시예 11 | 0 명 | 1 명 | 18 명 | 1 명 |
실시예 12 | 0 명 | 0 명 | 18 명 | 2 명 |
실시예 13 | 0 명 | 4 명 | 15 명 | 1 명 |
실시예 14 | 1 명 | 3 명 | 15 명 | 1 명 |
실시예 15 | 0 명 | 5 명 | 13 명 | 2 명 |
실시예 16 | 0 명 | 2 명 | 17 명 | 1 명 |
비교실시예 1 | 2 명 | 3 명 | 14 명 | 1 명 |
비교실시예 2 | 2 명 | 4 명 | 13 명 | 1 명 |
비교실시예 3 | 1 명 | 3 명 | 15 명 | 1 명 |
구분 | 용출량 (%) | |||
30분 | 1시간 | 2시간 | 3시간 | |
홍삼 엑기스 | 100 | 100 | 100 | 100 |
실시예 1 | 42 | 73 | 94 | 99 |
실시예 2 | 32 | 62 | 82 | 96 |
실시예 3 | 45 | 77 | 97 | 99 |
실시예 4 | 50 | 73 | 93 | 99 |
실시예 5 | 44 | 79 | 95 | 99 |
실시예 6 | 30 | 61 | 81 | 93 |
실시예 7 | 50 | 80 | 98 | 99 |
실시예 8 | 40 | 71 | 93 | 99 |
실시예 9 | 41 | 73 | 93 | 99 |
실시예 10 | 41 | 72 | 94 | 99 |
실시예 11 | 40 | 70 | 93 | 99 |
실시예 12 | 39 | 73 | 94 | 99 |
실시예 13 | 38 | 69 | 88 | 96 |
실시예 14 | 37 | 68 | 86 | 96 |
실시예 15 | 38 | 69 | 86 | 95 |
실시예 16 | 39 | 70 | 88 | 98 |
비교실시예 1 | 34 | 72 | 87 | 97 |
비교실시예 2 | 38 | 73 | 90 | 98 |
비교실시예 3 | 42 | 76 | 91 | 98 |
Claims (5)
- 홍삼 또는 인삼 엑기스 분말에서 선택된 1종 이상의 심지물질 50∼95 중량%에 지방산에스테르와 셀룰로오스 고분자물질이 3∼5 : 1로 혼합된 1차 벽재물질 1∼20 중량%를 심지물질에 유동층코팅기를 사용하여 코팅시켜 마이크로캡슐을 제조하거나, 상기 1차 코팅 위에 메타크릴산 공중합체 1∼20 중량%를 2차 벽재물질로 재차 유동층코팅기를 사용하여 2차 코팅시킨 입경 0.05∼3㎜의 홍삼 또는 인삼 엑기스 분말 함유 마이크로캡슐
- 제 1 항에 있어서, 상기 벽재물질인 지방산에스테르는 스테아린산, 팔미티산, 스테아릴스테아레이트, 쎄토스테아릴알콜, 스테아릴알콜, 글리세릴베헤네이트, 글리세릴모노스테이레이트, 글리세릴팔미토스테아레이트, 세틸알콜, 폴리옥시에칠렌스테아레이트, 소르비탄모노스테아레이트, 소르비탄모노팔미테이트등에서 선택된 1종 이상임을 특징으로 하는 마이크로캡슐
- 제 1항에 있어서, 상기 셀룰로오스 고분자물질은 메틸셀룰로오스, 에틸셀룰로오스, 히드록시프로필셀룰로오스, 저치환도히드록시프로필렌셀룰로오스, 히드록시프로필메틸셀룰로오스, 프탈산히드록시프로필메틸셀룰로오스, 히드록시프로메틸셀룰로오스아세테이트숙시네이트, 셀룰로오스아세테이트프탈레이트, 셀룰로오스아세테이트부틸레이트 등에서 선택된 1종 이상임을 특징으로 하는 마이크로캡슐
- 제 1항에 있어서, 상기 메타크릴산 공중합체는 상품명 유드라지트 L30 D-55, 콜리코트 MAE 30 DP에서 선택된 1종 이상의 메타크릴산-에틸아크릴레이트 공중합체임을 특징으로 하는 마이크로캡슐
- 제 1항에 있어서, 상기 홍삼 또는 인삼 엑기스 분말 함유 마이크로캡슐을 함유한 음료, 화장품, 제과제품
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2002-0003276A KR100526998B1 (ko) | 2002-01-21 | 2002-01-21 | 홍삼 및 인삼 엑기스 분말을 함유한 마이크로캡슐 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2002-0003276A KR100526998B1 (ko) | 2002-01-21 | 2002-01-21 | 홍삼 및 인삼 엑기스 분말을 함유한 마이크로캡슐 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20020031111A true KR20020031111A (ko) | 2002-04-26 |
KR100526998B1 KR100526998B1 (ko) | 2005-11-08 |
Family
ID=19718657
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR10-2002-0003276A KR100526998B1 (ko) | 2002-01-21 | 2002-01-21 | 홍삼 및 인삼 엑기스 분말을 함유한 마이크로캡슐 |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100526998B1 (ko) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20030081928A (ko) * | 2002-04-15 | 2003-10-22 | 이규환 | 홍삼을 주원료로 한 건강보조식품의 제조방법 및 그 건강보조식품 |
KR100466719B1 (ko) * | 2002-02-04 | 2005-01-17 | 주식회사 일화 | 홍삼 또는 인삼정분을 함유하는 구형의 미세캡슐 제조방법 |
KR100809920B1 (ko) * | 2006-09-22 | 2008-03-06 | 다윈이십일주식회사 | 장기 안정성이 우수한 인삼성분 미세캡슐의 제조방법 |
WO2012112116A1 (en) * | 2011-02-16 | 2012-08-23 | Wellbemed Sweden Ab | Foodstuff comprising an extract mixture |
KR101351680B1 (ko) * | 2007-03-22 | 2014-01-15 | 주식회사 엘지생활건강 | 마이크로 캡슐,그 제조방법 및 마이크로 캡슐을 포함하는기능성 조성물 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101637557B1 (ko) | 2014-03-28 | 2016-07-07 | 증평삼가공명품화사업단 | 키토산과 젤라틴을 이용한 쓴맛이 감소된 홍삼 추출물 함유 나노캡슐 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2613539B2 (ja) * | 1993-05-10 | 1997-05-28 | 大峰堂薬品工業株式会社 | 胃腸薬 |
JPH09103275A (ja) * | 1995-10-09 | 1997-04-22 | Riken Vitamin Co Ltd | 生薬エキス配合マイクロカプセルを含有する錠菓 |
WO1999052510A1 (en) * | 1998-04-09 | 1999-10-21 | Eurand International S.P.A. | Wettable microcapsules having hydrophobic polymer coated cores |
KR100370870B1 (ko) * | 1998-05-26 | 2003-07-12 | 코오롱제약주식회사 | 쓴맛이은폐된록시스로마이신과립제및그의제조방법 |
-
2002
- 2002-01-21 KR KR10-2002-0003276A patent/KR100526998B1/ko active IP Right Grant
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100466719B1 (ko) * | 2002-02-04 | 2005-01-17 | 주식회사 일화 | 홍삼 또는 인삼정분을 함유하는 구형의 미세캡슐 제조방법 |
KR20030081928A (ko) * | 2002-04-15 | 2003-10-22 | 이규환 | 홍삼을 주원료로 한 건강보조식품의 제조방법 및 그 건강보조식품 |
KR100809920B1 (ko) * | 2006-09-22 | 2008-03-06 | 다윈이십일주식회사 | 장기 안정성이 우수한 인삼성분 미세캡슐의 제조방법 |
KR101351680B1 (ko) * | 2007-03-22 | 2014-01-15 | 주식회사 엘지생활건강 | 마이크로 캡슐,그 제조방법 및 마이크로 캡슐을 포함하는기능성 조성물 |
WO2012112116A1 (en) * | 2011-02-16 | 2012-08-23 | Wellbemed Sweden Ab | Foodstuff comprising an extract mixture |
Also Published As
Publication number | Publication date |
---|---|
KR100526998B1 (ko) | 2005-11-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2020280997B2 (en) | A process to enhance the bioactivity of Ashwagandha extracts | |
RU2319500C2 (ru) | Композиции для профилактики или лечения поллиноза, аллергического нефрита, атопического дерматита, астмы или крапивницы | |
EP2070545A1 (en) | Oral compositions for the prevention and treatment of inflammatory disorders of the colon | |
KR20190135497A (ko) | 시나라 카르둔큘러스 및 시트러스 아우란티움 베르가미아의 추출물, 이들의 조합물, 및 이들을 함유하는 제제 | |
Zakynthinos et al. | Hippophae rhamnoides: safety and nutrition | |
US20200188468A1 (en) | A coated costus composition enriched with triterpenoids and a method of preparation of the same | |
RU2207866C2 (ru) | ПРИМЕНЕНИЕ ФОСФОЛИПИДНЫХ КОМПЛЕКСОВ ЭКСТРАКТОВ ИЗ vitis vinifera В КАЧЕСТВЕ ПРОТИВОАТЕРОСКЛЕРОТИЧЕСКИХ АГЕНТОВ | |
KR102231129B1 (ko) | 수면 장애 치료용 발레리안 뿌리 추출물 및 라벤더 오일의 조합물 | |
US9987323B2 (en) | Process to enhance the bioactivity of Ashwagandha extracts | |
JP2007277128A (ja) | 生活習慣病の予防・改善方法及び予防・改善剤 | |
CN101199347A (zh) | 一种排铅保健品及其制备方法 | |
KR100526998B1 (ko) | 홍삼 및 인삼 엑기스 분말을 함유한 마이크로캡슐 | |
CN106349318B (zh) | 一种五环三萜化合物在制备治疗肥胖症药物中的应用 | |
AU2012325600B2 (en) | Pharmaceutical composition regulating blood fat and preparation process thereof | |
CN107789562A (zh) | 一种药食同源的组合物在制备改善睡眠障碍或改善记忆功能减退药物或保健食品中的应用 | |
CN107692087A (zh) | 一种辅助降压的海参肠保健食品 | |
CN109549206A (zh) | 一种溶栓及预防心血管疾病的功能性食品及其制备方法 | |
KR20010009653A (ko) | 성기능 장애를 위한 치료용 조성물 | |
RU2436415C2 (ru) | Композиция биологически активных веществ на основе бетулина с регулируемой скоростью высвобождения компонентов для снижения степени алкогольного опьянения, предупреждения и снятия алкогольной интоксикации и похмельного синдрома | |
JPH06340542A (ja) | 薬用植物由来の骨疾患の予防・治療剤 | |
JP4610730B2 (ja) | カルシウム補給用の組成物 | |
CN110368456A (zh) | 一种有助于改善睡眠的竹叶黄酮组合物 | |
CN105246472B (zh) | 含有鸟氨酸和/或门冬氨酸的组合物及其应用 | |
US20230233642A1 (en) | Process to enhance the bioactivity of ashwagandha extracts | |
EP3006026A1 (en) | Pharmaceutical composition for treating anxiety containing l-theanine and baicalein |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
N231 | Notification of change of applicant | ||
N231 | Notification of change of applicant | ||
A302 | Request for accelerated examination | ||
E902 | Notification of reason for refusal | ||
AMND | Amendment | ||
E601 | Decision to refuse application | ||
AMND | Amendment | ||
J201 | Request for trial against refusal decision | ||
E902 | Notification of reason for refusal | ||
B701 | Decision to grant | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20121101 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20131017 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20141022 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20160120 Year of fee payment: 11 |
|
FPAY | Annual fee payment |
Payment date: 20161101 Year of fee payment: 12 |
|
FPAY | Annual fee payment |
Payment date: 20181025 Year of fee payment: 14 |